SOURCE: StockCall

StockCall

August 19, 2010 09:53 ET

Analyst Research on Dendreon and Amylin Pharmaceuticals - Biotech Stocks Looking Averagely Attractive

JOHANNESBURG, SOUTH AFRICA--(Marketwire - August 19, 2010) -  www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on Dendreon Corp. (NASDAQ: DNDN) and Amylin Pharmaceuticals Inc. (NASDAQ: AMLN). Register with us today at www.stockcall.com/ to have free access to these researches. 

The uncertainty surrounding heath care reform in the US has kept many investors away from the biotechnology industry. That coupled with the rise of generic alternatives in the US and Europe has prevented some biotechnology companies from making large gains. With all of that being said, innovation, product development and implementation reign paramount to a biotech company's success. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Dendreon Corp. and Amylin Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

Recent advancements in drugs that are designed to treat prostate cancer, hepatitis C and HIV have boosted some companies' sales higher. Despite reporting a loss of $143 million for this Q2, Dendreon Corp. has seen strong traders' support due to its Provenge drug sales for this quarter. Prostate cancer drug Provenge revenue shy rocketed from $25,000 last year to $2.8 million in the last quarter. Investors looking for free research on Dendreon Corp. are welcome to sign up at www.stockcall.com/DNDN190810.pdf for our new report. 

Also posting a loss this quarter is Amylin Pharmaceuticals Inc. which has seen sales of its injectable diabetes treatment Byetta plummet by 20%. Investors looking for complimentary research on Amylin Pharmaceuticals Inc. are welcome to sign up at www.stockcall.com/AMLN190810.pdf for our new report. 

While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. That coupled with new regulations that are still unclear could prove challenging to the industry. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information